Page 75 - Helicobacter pylori and Gastric Cancer: From Tumor microenvironment to Immunotherapy

26. Muro, K., et al., Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. J Clin Oncol, 2015. 33(3).
27. Bang, Y.J., et al., Relationship between PDL1 expression and clinical outcomes in patients with advanced gastric cancer treated with the antiPD- 1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol, 2015. 33(15).
28. Ohtsu, A., et al., Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study. 2015. 26: p. iv29-iv30.
29. Muro, K., Clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475) in KEYNOTE-012. 2015. 26: p. vii12.
30. Bang, Y.J., et al., Clinical outcomes and their correlation with gene
expression in patients with advanced gastric cancer treated with
pembrolizumab (MK-3475): KEYNOTE-012. 2015. 26: p. iv118.
31. Fuchs, C.S., et al., Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol, 2015.
33(15).
32. Fuchs, C., et al., Pembrolizumab (MK-3475) for patients with recurrent or
metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: The
phase 2 KEYNOTE-059 study. 2015. 26: p. iv29.
33. Ayers, M., et al., Relationship between immune gene signatures and clinical
response to PD-1 blockade with pembrolizumab (MK-3475) in patients with
advanced solid tumors. J Immunother Cancer, 2015. 3.
34. Oh, D.Y., et al., Avelumab (MSB0010718C), an anti-PD-LI antibody, as a
third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib JAVELIN Solid Tumor trial. J Clin Oncol, 2016. 34(4).
35. Kelly, R.J., et al., Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or
in combination, in patients with recurrent or metastatic
Immunotherapy Checkpoint Inhibition
Immuno checkpoint inhibition
69
73
3